<DOC>
	<DOCNO>NCT00749034</DOCNO>
	<brief_summary>Goal VPM development recombinant urease C-deficient listeriolysin express BCG vaccine strain ( VPM1002 ) safe , well tolerate efficacious vaccine TB resident endemic area person risk non-endemic area . The new live vaccine VPM1002 least potent currently use BCG vaccine cause few side effect ( Kaufmann , 2007 ; Grode et al. , 2005 ) . It formulate lyophilised bacteria resuspend intradermal injection . First application VPM1002 human male volunteer evaluate safety , local systemic tolerability well immunogenicity . The study dose-escalating sequential design comparison commercially available BCG . 80 volunteer Germany randomly allocate 4 group 20 volunteer stratify history BCG-vaccination .</brief_summary>
	<brief_title>Dose-Escalation Study Safety Immunogenicity VPM1002 Comparison With BCG Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male volunteer 18 55 year age . 2 . Healthy ( medical history , physical examination , vital sign , ECG laboratory test screen ) . 3 . No sign active latent tuberculosis infection . 4 . BMI 19 30 kg/m2 . 5 . Subjects must able willing comply study protocol , available willing complete study measurement sign Informed Consent form approve Ethics Committee . 6 . Intention travel endemic region tuberculosis ( Africa , Asia , former USSR ) reachable phone whole study period ( 6 month ) . 7 . Negative test HIV1 HIV2 , hepatitis B surface antigen antibody hepatitis C virus . 8 . No anamnestic evidence primary secondary immunodeficiency . 9 . No skin eczema lesion intend injection site . 10 . No anamnestic predisposition scar badly keloid formation . 11 . No vaccination eight week followup period current study . If vaccination necessary period , volunteer withdrawn study . 12 . No participation another clinical trial within 3 month study vaccination 6 month current study . 13 . Able willing abstain physical exercise 24 hour screen examination , 24 hour admission discharge clinic . 14 . No blood donation non studyrelated purpose entire duration study . 15. normal sonographic liver image For group volunteer vaccinate BCG vaccine : â€¢ TuberculinPPDinvivotest equal 10 mm baseline For group naive volunteer : â€¢ TuberculinPPDinvivoTest equal 1 mm baseline For volunteer 1. systemic disorder could interfere interpretation study result compromise health volunteer . 2 . BCGvaccination 10 year study vaccination . 3 . Acute fever fever last 7 day dose . 4 . Any malignant condition . 5 . Concomitant treatment medication may affect immune function 3 month study vaccination 6 month current study . 6 . Treatment blood product Immunoglobulins past 6 month end study . 7 . Any clinically significant laboratory abnormality screen blood sample . 8 . A history drug alcohol abuse . 9 . History anaphylaxis severe allergic reaction . 10 . Positive test drug abuse urine test screen admission . 11 . Known allergy component investigational reference product know history severe skin reaction Tuberculin test . 12 . Professional regular contact life animal food production .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Vaccination tuberculosis</keyword>
	<keyword>Safety immunogenicity VPM1002 comparison BCG</keyword>
</DOC>